ClinicalTrials.gg
CompletedNCT00945321Updated Jan 28, 2015Results posted

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

A Phase 1 interventional study of aprepitant 165 mg and Comparator: aprepitant 185 mg in Chemotherapy-Induced Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing fosaprepitant in Vomiting — 2 open to participants now, 2 under way, 1 of them phase 3. fosaprepitant · Vomiting.

Enrollment
20th of 26
42 · median 114
Started
2009
with 2 others
Phase 1
4 of 26
none open now
Registered
6th of 26
by date
Lead sponsor
11 of 26
Merck Sharp & Dohme LLC

Among the 26 studies testing fosaprepitant in Vomiting, this one is the 20th largest by enrollment, is one of 3 that started in 2009, is one of 4 in phase 1, and was the 6th registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 99 are open to participants now.

Browse Vomiting studies →

Open to participants now

2 of the 26 studies testing fosaprepitant in Vomiting are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fosaprepitant

fosaprepitant: first FDA approval 2008 (EMEND), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing fosaprepitant in Vomiting, or all of them as a file.
02

Study summary

This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.

03

Conditions studied

  • Chemotherapy-Induced Nausea and Vomiting

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is in good health
  • Subject is a nonsmoker
  • Subject is willing to comply with the study restrictions

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of any illness that might confound the results of the study or might make participation in the study unsafe
  • Subject has a history of stroke, seizures, or major neurological disorder
  • Subject has a history of cancer
  • Subject consumes more than two alcoholic drinks per day
  • Subject consumes more than three caffeinated beverages daily
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Active comparator
    1

    aprepitant 165 mg

    Drug: aprepitant 165 mg

  • Active comparator
    2

    aprepitant 185 mg

    Drug: Comparator: aprepitant 185 mg

  • Experimental
    3

    fosaprepitant 150 mg

    Drug: Comparator: fosaprepitant 150 mg

  • Experimental
    4

    aprepitant with food

    Drug: Comparator: aprepitant with food

Interventions

  • Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.

  • Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.

  • Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.

  • DrugComparator: aprepitant with food

    Drug page: Aprepitant

    Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg

    Time frame: Through 72 Hours Postdose

  2. Peak Plasma Concentration (Cmax) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg.

    Time frame: Through 72 Hours Postdose

07

Results

Posted Jun 30, 2010

Participant flow

Period 1
Participant flow — Period 1
MilestoneA/B/C/DB/C/A/DC/A/B/DA/C/B/EB/A/C/EC/B/A/E
Started777777
Completed777767
Not completed000010
Withdrew: Adverse event000010
Period 2
Participant flow — Period 2
MilestoneA/B/C/DB/C/A/DC/A/B/DA/C/B/EB/A/C/EC/B/A/E
Started777767
Completed777767
Not completed000000
Period 3
Participant flow — Period 3
MilestoneA/B/C/DB/C/A/DC/A/B/DA/C/B/EB/A/C/EC/B/A/E
Started777767
Completed777767
Not completed000000
Period 4
Participant flow — Period 4
MilestoneA/B/C/DB/C/A/DC/A/B/DA/C/B/EB/A/C/EC/B/A/E
Started777767
Completed777766
Not completed000001
Withdrew: Lost to follow-up000001

Outcome measures

PrimaryArea Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg
Time frame:
Through 72 Hours Postdose
Reported as:
Mean · ng•hr/mL
Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg
ng•hr/mL165 mg Aprepitant (Fasted State)185 mg Aprepitant (Fasted State)150 mg Fosaprepitant Dimeglumine (Fasted State)165 mg Aprepitant (Light)165 mg Aprepitant (High-Fat)185 mg Aprepitant (Light)185 mg Aprepitant (High-Fat)
Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg34589 ± 39.739053 ± 37.537375 ± 39.537795 ± 48.450172 ± 22.051146 ± 27.260578 ± 57.5
Statistical analysis
  • 165 mg Aprepitant (Fasted State) vs 150 mg Fosaprepitant Dimeglumine (Fasted State) · two one-sided tests · p = 0.001 (Hochberg's step-up procedure was applied to preserve the overall alpha level for the primary hypothesis that involved comparison at two oral dose levels.) · Least-squares mean ratio: 0.93 · 95% CI 0.84 to 1.02The P-value obtained was the maximum of two P-values from two one-sided tests (GMR (Oral/IV) ≤0.80 vs. GMR\>0.80 and GMR≥1.25 vs. GMR\<1.25).
  • 185 mg Aprepitant (Fasted State) vs 150 mg Fosaprepitant Dimeglumine (Fasted State) · two one-sided tests · p = <0.001 (Hochberg's step-up procedure was applied to preserve the overall alpha level for the primary hypothesis that involved comparison at two oral dose levels) · Least-squares mean ratio: 1.05 · 95% CI 0.96 to 1.15The P-value obtained was the maximum of two P-values from two one-sided tests (GMR (Oral/IV) ≤0.80 vs. GMR\>0.80 and GMR≥1.25 vs. GMR\<1.25).
  • 165 mg Aprepitant (Fasted State) vs 165 mg Aprepitant (High-Fat) · Least-squares mean ratio: 1.47 · 90% CI 1.23 to 1.76
  • 165 mg Aprepitant (Fasted State) vs 165 mg Aprepitant (Light) · Least-squares mean ratio: 1.08 · 90% CI 0.88 to 1.32
  • 185 mg Aprepitant (Fasted State) vs 185 mg Aprepitant (High-Fat) · Least-squares mean ratio: 1.22 · 90% CI 1.01 to 1.46
  • 185 mg Aprepitant (Fasted State) vs 185 mg Aprepitant (Light) · Least-squares mean ratio: 1.43 · 90% CI 1.16 to 1.75
PrimaryPeak Plasma Concentration (Cmax) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg.
Time frame:
Through 72 Hours Postdose
Reported as:
Mean · ng/mL
Peak Plasma Concentration (Cmax) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg.
ng/mL165 mg Aprepitant (Fasted State)185 mg Aprepitant (Fasted State)165 mg Aprepitant (Light)165 mg Aprepitant (High-Fat)185 mg Aprepitant (Light)185 mg Aprepitant (High-Fat)
Peak Plasma Concentration (Cmax) Following Single Dose Administration of Aprepitant 165 mg or 185 mg and Fosaprepitant 150 mg.1738 ± 30.81636 ± 31.21870 ± 33.32362 ± 38.52116 ± 14.81995 ± 35.2
Statistical analysis
  • 165 mg Aprepitant (Fasted State) vs 165 mg Aprepitant (High-Fat) · Least-squares mean ratio: 1.33 · 90% CI 1.13 to 1.56
  • 165 mg Aprepitant (Fasted State) vs 165 mg Aprepitant (Light) · Least-squares mean ratio: 1.04 · 95% CI 0.86 to 1.25
  • 185 mg Aprepitant (Fasted State) vs 185 mg Aprepitant (High-Fat) · Least-squares mean ratio: 1.14 · 90% CI 0.96 to 1.34
  • 185 mg Aprepitant (Fasted State) vs 185 mg Aprepitant (Light) · Least-squares mean ratio: 1.40 · 90% CI 1.16 to 1.68

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
165 mg Aprepitant—0/41 (0%)12/41 (29.3%)
185 mg Aprepitant—1/42 (2.4%)13/42 (31%)
150 mg Fosaprepitant Dimeglumine—0/41 (0%)15/41 (36.6%)
165 mg Aprepitant (Fed State)—0/21 (0%)6/21 (28.6%)
185 mg Aprepitant (Fed State)—0/20 (0%)3/20 (15%)
Most frequent serious events
Most frequent serious events
Event165 mg Aprepitant185 mg Aprepitant150 mg Fosaprepitant Dimeglumine165 mg Aprepitant (Fed State)185 mg Aprepitant (Fed State)
Accidental OverdoseInjury, poisoning and procedural complications0/411/420/410/210/20
Most frequent other events
Showing 10 of 23
Most frequent other events
Event165 mg Aprepitant185 mg Aprepitant150 mg Fosaprepitant Dimeglumine165 mg Aprepitant (Fed State)185 mg Aprepitant (Fed State)
HeadacheNervous system disorders9/416/426/411/211/20
SomnolenceNervous system disorders0/410/420/412/211/20
DizzinessNervous system disorders3/413/421/410/210/20
Oropharyngial PainRespiratory, thoracic and mediastinal disorders0/410/421/410/211/20
Infusion Site IndurationGeneral disorders0/411/422/410/210/20
Nasal CongestionRespiratory, thoracic and mediastinal disorders2/410/422/410/210/20
Abdominal Pain UpperGastrointestinal disorders0/411/420/411/210/20
DiarrhoeaGastrointestinal disorders0/410/420/411/210/20
Chest PainGeneral disorders0/410/420/411/210/20
Infusion Site MassGeneral disorders0/410/420/411/210/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean27.8 (18 to 43)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female10
Male32
Height
Height(Centimeters)All Participants
Mean172.9 (151.1 to 190.5)
Weight
Weight(Kilograms)All Participants
Mean74.2 (44.9 to 91.2)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Shadle CR, Murphy MG, Liu Y, Ho M, Tatosian D, Li SX, Blum RA. A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects. Clin Pharmacol Drug Dev. 2012 Jul;1(3):93-101. doi: 10.1177/2160763X12447304. PubMed 27121336 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2009
First posted
Jul 24, 2009
Start
Feb 2009
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Jun 30, 2010
Last update
Jan 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00945321
Responsible party
Sponsor
First posted
Jul 24, 2009
Start date
Feb 2009
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Jun 30, 2010
Last update
Jan 28, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fosaprepitant · Aprepitant

Start the discussion